L-Carnitine: a potential treatment for blocking apoptosis and preventing skeletal muscle myopathy in heart failure.

Skeletal muscle in congestive heart failure is responsible for increased fatigability and decreased exercise capacity. A specific myopathy with increased expression of fast-type myosins, myocyte atrophy, secondary to myocyte apoptosis triggered by high levels of circulating tumor necrosis factor-alpha (TNF-alpha) has been described. In an animal model of heart failure, the monocrotaline-treated rat, we have observed an increase of apoptotic skeletal muscle nuclei. Proapoptotic agents, caspase-3 and -9, were increased, as well as serum levels of TNF-alpha and its second messenger sphingosine. Treatment of rats with L-carnitine, known for its protective effect on muscle metabolism injuries, was found to inhibit caspases and to decrease the levels of TNF-alpha and sphingosine, as well as the number of apoptotic myonuclei. Staurosporine was used in in vitro experiments to induce apoptosis in skeletal muscle cells in culture. When L-carnitine was applied to skeletal muscle cells, before staurosporine treatment, we observed a reduction in apoptosis. These findings show that L-carnitine can prevent apoptosis of skeletal muscles cells and has a role in the treatment of congestive heart failure-associated myopathy.

[1]  G. Bruno,et al.  Determination of L-carnitine, acetyl-L-carnitine and propionyl-L-carnitine in human plasma by high-performance liquid chromatography after pre-column derivatization with 1-aminoanthracene. , 1996, Journal of chromatography. B, Biomedical applications.

[2]  M. Kaneki,et al.  Skeletal muscle apoptosis after burns is associated with activation of proapoptotic signals. , 2000, American journal of physiology. Endocrinology and metabolism.

[3]  M. Sandri,et al.  Apoptosis of skeletal muscle myofibers and interstitial cells in experimental heart failure. , 1998, Journal of molecular and cellular cardiology.

[4]  R. Lenkinski,et al.  Contribution of Skeletal Muscle Atrophy to Exercise Intolerance and Altered Muscle Metabolism in Heart Failure , 1992, Circulation.

[5]  K. Kandror,et al.  Comparison of glucose-transporter-containing vesicles from rat fat and muscle tissues: evidence for a unique endosomal compartment. , 1995, The Biochemical journal.

[6]  R. Ferrari,et al.  Apoptosis in the skeletal muscle of patients with heart failure: investigation of clinical and biochemical changes , 2000, Heart.

[7]  R. Ribacchi,et al.  Selective trophic effect of L-carnitine in type I and IIa skeletal muscle fibers. , 1994, Kidney international.

[8]  M. Volterrani,et al.  Improved exercise tolerance after losartan and enalapril in heart failure: correlation with changes in skeletal muscle myosin heavy chain composition. , 1998, Circulation.

[9]  C. Leprotti,et al.  Skeletal muscle myosin heavy chains in heart failure: correlation between magnitude of the isozyme shift, exercise capacity, and gas exchange measurements. , 1998, American heart journal.

[10]  M. Palacín,et al.  Insulin-dependent protein trafficking in skeletal muscle cells. , 1998, The American journal of physiology.

[11]  G. Tremblay,et al.  Insulin-like effects of a physiologic concentration of carnitine on cardiac metabolism , 2001, Molecular and Cellular Biochemistry.

[12]  J. Jaffrezou,et al.  L‐carnitine prevents doxorubicin‐induced apoptosis of cardiac myocytes: role of inhibition of ceramide generation , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[13]  A. Angelini,et al.  Apoptosis in the skeletal muscle of rats with heart failure is associated with increased serum levels of TNF-alpha and sphingosine. , 2001, Journal of molecular and cellular cardiology.

[14]  R. Betto,et al.  The role of sphingolipids in the control of skeletal muscle function: a review , 1999, The Italian Journal of Neurological Sciences.

[15]  H. Fillit,et al.  Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. , 1990, The New England journal of medicine.

[16]  C. Catani,et al.  Specific changes in skeletal muscle myosin heavy chain composition in cardiac failure: differences compared with disuse atrophy as assessed on microbiopsies by high resolution electrophoresis. , 1996, Heart.

[17]  M. Piepoli,et al.  Predictors of exercise capacity in chronic heart failure. , 1994, European heart journal.

[18]  R. Gottlieb,et al.  Regulation of the activity of caspases by L‐carnitine and palmitoylcarnitine , 2000, FEBS letters.

[19]  J. Arenas,et al.  Myocardial carnitine and carnitine palmitoyltransferase deficiencies in patients with severe heart failure. , 2000, Biochimica et biophysica acta.

[20]  I. Grierson,et al.  Apoptosis in multinucleated skeletal muscle myotubes. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[21]  G. Peluso,et al.  Carnitine: An osmolyte that plays a metabolic role , 2000, Journal of cellular biochemistry.

[22]  A. Rizk,et al.  Plasma carnitine levels as a marker of impaired left ventricular functions , 2000, Molecular and Cellular Biochemistry.

[23]  D. Zechner,et al.  Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. , 1996, The Journal of clinical investigation.

[24]  P. Poole‐Wilson,et al.  Abnormalities of skeletal muscle in patients with chronic heart failure. , 1988, International journal of cardiology.

[25]  M. Sandri,et al.  Apoptosis and atrophy in rat slow skeletal muscles in chronic heart failure. , 1999, The American journal of physiology.

[26]  R. Ferrari,et al.  The propionyl-L-carnitine hypothesis: an alternative approach to treating heart failure. , 1997, Journal of cardiac failure.

[27]  M. Sandri,et al.  Apoptosis of skeletal muscles during development and disease. , 1999, The international journal of biochemistry & cell biology.

[28]  A. Angelini,et al.  Beneficial Effects on Skeletal Muscle of the Angiotensin II Type 1 Receptor Blocker Irbesartan in Experimental Heart Failure , 2001, Circulation.

[29]  R. Bell,et al.  Lipid biochemistry: functions of glycerolipids and sphingolipids in cellular signaling , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[30]  A. Louis,et al.  Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ‐2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001 , 2001, European journal of heart failure.

[31]  R. Ferrari,et al.  Skeletal muscle myosin heavy chain expression in rats with monocrotaline-induced cardiac hypertrophy and failure. Relation to blood flow and degree of muscle atrophy. , 1998, Cardiovascular research.

[32]  L. D. Libera,et al.  The role of sphingosine in inducing skeletal muscle apoptosis and atrophy in heart failure , 2000 .

[33]  R. McCARTER,et al.  Metabolic adaptations in skeletal muscle overexpressing GLUT4: effects on muscle and physical activity , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[34]  S. Anker,et al.  Cachexia in heart failure is bad for you. , 1998, European heart journal.

[35]  G. Dorn,et al.  Sphingosine Mediates the Immediate Negative Inotropic Effects of Tumor Necrosis Factor-α in the Adult Mammalian Cardiac Myocyte* , 1997, The Journal of Biological Chemistry.

[36]  R. Ferrari,et al.  Acute and Chronic Effects of Propionyl-L-Carnitine on the Hemodynamics, Exercise Capacity, and Hormones in Patients with Congestive Heart Failure , 1998, Cardiovascular Drugs and Therapy.